Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-20
2007-11-20
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252180, C514S272000, C514S274000, C514S318000, C514S336000, C514S343000, C544S123000, C544S295000, C544S315000, C544S331000, C546S194000, C546S276400, C546S283400
Reexamination Certificate
active
10488576
ABSTRACT:
Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
REFERENCES:
patent: 2 306 108 (1997-04-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 00/64422 (2000-11-01), None
patent: WO 01/38324 (2001-05-01), None
patent: WO 01/66539 (2001-09-01), None
patent: WO 01/66540 (2001-09-01), None
patent: WO 02/24680 (2002-03-01), None
De Laszlo et al., “Pyrroles and other heterocycles as inhibitors of p38 kinase”, Bioorg. Med. Chem. Lett., vol. 8, 1998, pp. 2689-2694.
De Laszlo et al., “Potent, orally abosorbed glucagon receptor antagonists”, Bioorg. Med. Chem. Lettl, vol. 9, 1999, pp. 641-646.
Liveton et al., “Design and Synthesis of Potent, Selective and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase”, J. Med. Chem., vol. 42, No. 12, 1999, pp. 2180-2190.
Kalmes et al., “Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor”, Febs Letters, vol. 444, No. 1, 1999. pp. 71-74.
Wermuth, C.G. (ed.), “Chapter 13: Molecular Variations Based on Isosteric Replacements”,The Practice of Medicinal Chemistry, pp. 204-237, Academic Press Ltd., Copyright (1996), XP-002190259.
Dean David Kenneth
Naylor Antoinette
Takle Andrew Kenneth
Wilson David Matthew
Dentz Bernard
Hsu Grace C.
Kinzig Cjarles M.
McCarthy Mary E.
SmithKline Beechum P.L.C.
LandOfFree
Pyridylfurans and pyrroles as Raf kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridylfurans and pyrroles as Raf kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridylfurans and pyrroles as Raf kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3866576